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Purpose/Objective: To evaluate through Doppler ultrasound the 
intratumoral vascularization of uveal melanoma (UM) at diagnosis as a 
sign of tumoral activity, and to quantify its presence after treatment 
with brachytherapy. 
Materials and Methods: 50 cases of UM were treated with 
brachytherapy from July 2005 to June2010. 26 men and 24 women 
with an average age of 60. 70% melanotic, 18% amelanotic and 12% 
mixed. Location: 30% posterior, 16% postequatorial, 22% equatorial, 
20%peripheral and 12% in ciliary body. Mean basal size and apical 
thickness at diagnosis: 12.1 x 5.6 mm (SD 3.0-5.6). A 125-Iodine 
plaque was used in 70% of cases and 106-Ruthenium in 28%. 
Transpupillary thermotherapy (TTT) was associated in 10 cases. The 
apical dose was 85 Gy. Mean follow-up was of 29 months (13.7-69 
months). Duplex Doppler scans (gray scale and Doppler scans) were 
done at diagnosis and every 6months after treatment. Parameters 
evaluated: presence of intratumoral vessels, systolic peak velocity 
(SPV), end-diastolic velocity (EDV) and resistance index (RI= syst-
diast/syst). 
Results: Doppler detected intratumoral vascularization at diagnosis in 
21 of 50 cases (42%): vascularization persisted in 7 cases at 6, 12 and 
18 months. At 24 months only persisted 5/31, at 30 months 3/20, at 
36 months 1/12, at 42 months 1/6, at 48 months 1/3, at 54 months 
1/2 and at 60 months 0/1. Mean systolic peak velocity at diagnosis 
was 25.2±16.1 cm/s and 15.82±10.5 at 6 months. The treatment had 
asignificant impact on the detection of tumour vessels (p=0.035), 
controlled by age, sex, maximum tumoral diameter and tumoral 
thickness in a logistic regression model. Mean resistance index (RI) 
was lower in tumours before treatment (0.50 vs 0.59, p=0.0047). Out 
of 6 tumours with persistent signal during follow-up, 4 were in 
regression, 1 large tumour recurred and was enucleated, and another 
large one developed metastases. 8 avascular tumors at diagnosis 
experienced new vascularization during follow-up: 1 recurred and was 
enucleated and the other 7 showed ophthalmoscopic and echographic 
regression, and vascularization eventually disappeared. 4 of them 
developed neovascular glaucoma (NVG). Reduction of the apical 
thickness was more significant in initially vascularized tumors that had 
lost the Doppler signal than in tumors that remained avascular or 
vascular at 6months (p=0.365). The SPV dropped significantly at 6 
months (p=0,028) but EDVdid not (p=0.116). 
Conclusions: The non-invasive quantification of neovascular blood 
flow using pulsed Doppler for UM treated with brachytherapy offers a 
new diagnostic modality to evaluate the tumour activity. Most UM lose 
their Doppler signal in the first 6 months. Persistent intratumoral 
vascularization seems to relate to large tumours, recurrence or 
appearance of vascular congestion. The new vascularization cases can 
be explained by the persistence of old vessels, tumor recurrence or 
presence of NVG.  
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Purpose/Objective: Hilar cholangiocarcinoma (Klatskin tumours) are 
rare tumours with poor prognosis. The purpose of this work was to 
determine efficacy, toxicity, and patterns of recurrence in patients 
treated with endobiliary radiotherapy (RT) and external beam RT 
(EBRT) with chemotherapy. 
Materials and Methods: From Aug 2005 to July 2012, 65 patients with 
locally advanced non-metastatic hilar cholangiocarcinoma and were 
studied. All the patients presented with jaundice and required 
percutaneous biliary drainage. Endobiliary RT using HDR – Iridium 192 
(median dose 14 Gy/4# b.i.d), was delivered through the PTBD 
catheter which was followed by metal stenting. Twenty two (34%) 
patients received only endobiliary RT, while 27 (41%) patients after 
brachytherapy were further treated with concurr (median dose 
45Gy/25#). Sixteen (25%) patients in who were referred after metal 
stenting received Intensity modulated radiotherapy to a dose of 
57Gy/25# with concurrent Inj. Gemcitabine (300mg/mt2 weekly). 
Histopathological diagnosis was available in 50 patients (77%).  
Results: Median follow up for whole group was 7 months (range 1-31 
months). Twelve patients had complete response, 30 patients had 
partial response and 12 patients had stable disease, while 11 patients 
had locally progressive disease after radiation. Twenty one patients 
were alive at last follow up. The median overall survival (OAS) was 7 
months and one year OAS and Cancer specific survival (CSS) was 44% 
and 51% for whole group. Patients receiving endobiliary combined 
with chemoradiation or high dose chemoradiation alone had better 
survival as compared to patients receiving only endobiliary RT at 1 
year (55% vs.17%, p=0.001). The main sites of distant disease 
progression were liver and peritoneum. Thirty one patients (48%) 
developed cholangitis of which 8 patients succumbed to it. Four 
patients had late radiation toxicity, of these 3 had hematemesis due 
to duodenitis and one had radiation induced stricture at 
gastroesophageal junction requiring dilatation. 
Conclusions: These encouraging results suggest that endobiliary 
radiation in addition to chemoradiation is feasible with acceptable 
toxicity in unresectable Klatskin tumors and leads to better outcome 
as compared to those receiving only endobiliary RT alone. 
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Purpose/Objective: Keloids are challenging lesions to treat with high 
rates of recurrence. There are a multitude of treatment options 
available with various rates of success. Evidence has shown surgical 
resection followed by RT to have the highest level of local control and 
numerous reports have shown control rates of 65 – 90% with adjuvant 
external beam RT. Prior studies have demonstrated a spectrum of 
aggressiveness for keloids. Secondary keloids or lesions that have 
undergone prior resection and then recurred are often refractory to 
further treatment with higher rates of recurrence. Keloids that recur 
after combined surgery and EBRT are especially difficult cases and 
limited in therapy options. The objective of our study was to 
determine the efficacy of surgical resection of keloids followed by 
HDR brachytherapy for management of lesions at high risk for 
recurrence.  
Materials and Methods: This study is a retrospective analysis of 18 
patients representing 29 keloids found on various body sites including 
the chest wall, axilla, breast, ear, pelvis, chin, cheek, neck, back, 
shoulder, and abdomen, treated at Montefiore Medical Center 
between 1996 and 2011. Our study population consisted of mainly 
secondary lesions already treated in the past with the combination of 
surgery and EBRT, lesions treated with surgery alone, or primary 
keloids deemed to be at a high risk for recurrence due to their size 
and location. The treatment in this study consisted of complete 
surgical excision with placement of hollow brachytherapy catheters, 
immediately followed by HDR Iridium-192 brachytherapy to a total 
dose of 15Gy in 3 fractions, over 3 consecutive days, prescribed to a 
1cm depth. Endpoints assessed included recurrence rate, treatment 
complications, and side effects. 14 lesions had undergone prior 
resection(s) and external beam radiation, 6 had previously received 
surgery alone, and 9 were primary lesions. The two most common 
sites were earlobe and chest wall. The mean age at treatment was 43 
(range 23-64 years).  
Results: The mean follow up in our study was 62 months (range 12-192 
months). Analysis of the data demonstrated a recurrence-free rate of 
89.6% (26/29 lesions). Two of the recurrences had received previous 
surgery and EBRT and one was a primary keloid with no prior 
treatment. 7 patients experienced delayed wound healing but 
eventually had a full recovery. 3 patients had post-operative 
infections at the surgical site that were successfully treated. Two 
patients experienced mild intermittent parasthesias at the treatment 
site and one complained of mild pruritis post-treatment. For the other 
26 lesions, there was an improvement in keloid symptoms including 
pain, parasthesias, and pruritis. 
Conclusions: Surgical resection and adjuvant HDR Iridium-192 
brachytherapy provide excellent and enduring levels of local control 
for keloid lesions at high risk for recurrence and are well tolerated 
with acceptably minimal long term side effects with a mean follow up 
of 62 months.  
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Purpose/Objective: The aim of this study was to evaluate the 
feasibility, safety and the early clinical results of a new procedure of 
2nd ESTRO Forum 2013   S377 
interstitial brachytherapy (BRT) in the anal canal based on RM 
guidance. 
Materials and Methods: After a month from the end of the combined 
treatment RTCT, all the patients got a clinical examination, a PET-CT 
and a MRI. The prescribed brachytherapy target volume (TV) was 
individuated, supported by a radiologist, by MRI performed with 
vaginal applicator (MRI compatible) positioned in the anus. With a 
MUPIT applicator (Elekta©) in situ a CT simulation was performed. CT 
images were fused with MRI by deformable co-registration 
(Velocity©). A treatment pre-plan was created in order to have 
information on the optimal position of the needles. Then the needles 
were positioned according to the indications of the pre-treatment 
plan. Afterward the patient underwent again a CT scan and the 
definitive treatment plan was created on Oncentra Brachy© console. 
Results: From February to June 2012, we treated 4 patients. 3 
patients had histological diagnosis of squamous cell anal canal 
carcinoma (SCACC), instead 1 patient was a low rectum 
adenocarcinoma. The median age was 61,5 (range 49-78). There were: 
2 patients cT2N0M0, 1 patient cT4N0M0 and1 patient cT4N2M0. A 
patient didn't ultimate the RT-CT combined treatment for toxicity. No 
complications were observed during and after the implant. The early 
follow up indicates no episodes of common complications at the first 
follow-up. Three patients had a complete response without tumor 
evidence and were alive without local recurrence or metastases. The 
patient that didn't ultimate RT-CT treatment had a local persistance. 
The dosimetric analysis showed that the mean TV was 16,03 cc and 
the mean TV covered by almost 100% of dose was 14.73 cc. The mean 
percentage of TV covered by less than 100% of dose was 4,9%. 
Conclusions: The integration of MRI guidance in BRT procedures 
seems to offer a better evaluation of the pelvis district adapting plan 
of treatment at the TV. Patients had a good compliance and no 
episodes of complication for now. To evaluate the clinical results in 
terms of local control and survival we need a longer follow up and a 
more representative sample. 
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Purpose/Objective: The first treatments with INTRABEAM ® system 
(Carl Zeiss SAS) using low energy X-rays were performed in our 
institution in October 2011. Between 2004 and 2011 an electron linear 
accelerator was used for intraoperative irradiation of the breast for 82 
patients. 
Materials and Methods: Fifty-nine patients of mean age 71 years [59-
87] have now been treated with INTRABEAM ®. For each, the radiation 
dose required was 20 Gy to the surface of the surgical margin in a 
single fraction. With the linear accelerator, 21 Gy were prescribed to 
the 90% depth dose of the chosen energy. The system INTRABEAM ® 
produces low energy photons from a 50 kV and 40μA source while 
preceding irradiation technique used electrons energy of 6 or 9 MeV. 
The isotropy of the low energy photon beam and the dose rate were 
measured before each treatment with a specific system and a 
calibrated ionization chamber. During irradiation with electrons, we 
realized an 'in vivo' measurement with a semiconductor placed at the 
tumor bed by the surgeon and the radiotherapist during the 
positioning of the applicator. With the new technique, sterile 
applicators with variable diameters from 3 to 5 cm are selected to 
exactly fit the surgical cavity, thus allowing a homogeneous spherical 
irradiation. In our previous technique, the tumor bed 'flattened' was 
systematically located 2 cm from the edge of the applicator (4 to 6 
cm in diameter) to get a sufficient safety margin for processing. 
Results: With INTRABEAM ®, the dose attenuation is rapid (5.4 Gy at 1 
cm from the applicator surface), thereby reducing damage to 
surrounding healthy tissue. For treatment, mobile system is installed 
in one of two operating ambulatory surgery designed in accordance 
with radiation protection standards and does not require as before the 
immobilization of a radiotherapy bunker. The average time needed to 
deliver the dose was 27 minutes [20-53] for 59 patients using the low 
energy photon technique. This time depends on the size of the 
applicator and is longer than the 11 minutes used before to deliver 
the prescribed dose with electrons. However, the total time needed 
for the room and the staff is not more important with INTRABEAM ® 
system as before. 
Conclusions: The shift from breast intraoperative radiotherapy using a 
linear accelerator to INTRABEAM® was realized with no major 
problems in our institution. Using this new system has improved the 
workflow of radiotherapy and surgery, and thus increases the number 
of patients that can benefit from this technique. 
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Purpose/Objective: In the last ten years, intraoperative radiotherapy 
has been used extensively in the clinical setting as the exclusive mode 
of partial breast irradiation or as tumor bed boost during BCS. A 
careful diagnostic evaluation is essential for the choice of the most 
appropriate treatment. Most international guidelines recommend a 
multidisciplinary approach for patients with breast cancer. The 
multidisciplinary team provide to establish quality standards in the 
multiple aspects of the treatment and may be particularly important 
for a procedure as IORT in which different professionals must work 
together for the successful implementation of the treatment. 
Materials and Methods: In our center, since February 2005 we treated 
about 500 cases of breast cancer with IORT and since January 2011, 
all patients were evaluated by the multidisciplinary team made up of 
surgeon, radiologist, radiation oncologist, medical oncologist, 
pathologist, radiographers and nurses. The selection of patients to be 
able to be submitted to IORT exclusively takes place, in agreement 
with the surgeon, on the basis of the ASTRO guidelines, all other 
patients are treated with EBRT and intraoperative boost. One of the 
main limitations in the use of IORT is the absence of pathology 
information; in our center all patients received core-biopsy with the 
evaluation of predictive parameters (histology, grading, Her2, ER, 
PgR, Ki67). During the surgery extemporaneous histological 
examination is performed to evaluate the surgical margins and the 
sentinel lymph node. 
Results: Since January 2011 to October 2012 in our hospital 152 
patients were treated with BCS and IORT. All patients were evaluated 
by the multidisciplinary team before and after surgery.  
37 patients, had a biopsy compliant with the ASTRO criteria and 
received IORT exclusively, 115 received anticipated boost. 
Histologically, three patients treated with IORT exclusive, were not 
fully compliant with the ASTRO criteria: in one case there was 
evidence of neoplastic thrombus in the sentinel node, in the other 
case the grading was 3 and in the last case it was a lobular form. 
Conclusions: An integrated, multidisciplinary approach is desiderable 
to treat all patients. We consider IORT a safe procedure, with good 
cosmetic results, allowing more women to have access to breast 
conserving therapy; a careful selection of patients who may benefit 
from a partial breast irradiation is needed. We believe that the core- 
biopsy examination can be very predictive and therefore mandatory 
before an exclusive treatment.The close and constant collaboration 
with the surgeon and the pathologist has been essential in the 
improvement of the entire procedure. 
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Purpose/Objective: The use of low energy X-ray radiotherapy is not 
always done in ideal conditions with the beam perpendicular to the 
surface. It is therefore important to know what will be the impact of 
the angle made by the applicator on the dose distribution. For this we 
have developed a software based on a Monte Carlo code. 
Materials and Methods: We use a papillon50 emitting 50 kV X-ras with 
applicators of different diameters (22, 25 and 30 mm). The apparatus 
and applicators were modeled with the Monte Carlo code PENELOPE. 
The validation of this model was made by comparing calculations and 
measurements by ionization chamber and films gafchromics EBT2. It 
